Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07808333

PHASE2

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Sponsor: University of Chicago

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether a high-dose vitamin B3 supplement called nicotinamide can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment. The main question it aims to answer is: Does adding nicotinamide to standard glaucoma therapy slow the rate of thinning of the inner retinal nerve cell layer (measured by a non-invasive eye scan) compared to standard therapy alone over 12 months? Participants will be randomly assigned to one of two groups. Participants in the treatment group will take nicotinamide tablets by mouth, starting at a lower dose (1.5 grams per day) for the first 6 weeks and increasing to the full dose (3.0 grams per day) for the remainder of the 12-month study. Participants in the control group will continue their standard glaucoma care without the supplement. Researchers will compare retinal imaging measurements between the two groups to see whether nicotinamide reduces the rate of retinal nerve cell thinning over time.

Official title: NADIR Trial: A Principal Investigator-Initiated, Single-Center, Open-Label, Active-Controlled Phase 2a Study of High-Dose Nicotinamide (Vitamin B3) Supplementation in Adults With Mild to Moderate Primary Open-Angle Glaucoma (POAG)

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2027-06-01

Completion Date

2029-10-31

Last Updated

2026-09-08

Healthy Volunteers

Conditions

Glaucoma, Open-angle Primary Open Angle Glaucoma (POAG)

Interventions

DRUG

Nicotinamide

Immediate-release nicotinamide 500 mg tablets (NDC 0-80681-01900; Rugby Laboratories / Contract Pharmacal Corp, Hauppauge NY). Titration phase: 500 mg three times daily (1.5 g/day total) for 6 weeks. Maintenance phase: 1,500 mg twice daily (three 500 mg tablets per administration, twice daily; 3.0 g/day total) from Week 7 through Month 12. Administered orally with meals. Dispensed and tracked by the University of Chicago Institutional Drug Service (IDS) Pharmacy under IND 184022.

OTHER

Standard Glaucoma Therapy

Individualized intraocular pressure-lowering therapy per the 2026 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern. Includes topical prostaglandin analog eye drops and/or selective laser trabeculoplasty, with clinical monitoring by optical coherence tomography, standard automated perimetry, and intraocular pressure measurement at 3 to 6 month intervals based on disease status.

Inclusion Criteria: * Age 40 to 80 years, inclusive * Diagnosis of primary open-angle glaucoma (POAG) in at least one eye, confirmed by a licensed ophthalmologist or optometrist based on characteristic optic nerve head changes and/or visual field defects with an open anterior chamber angle * Mild to moderate glaucoma severity in the study eye: Humphrey Visual Field 24-2 mean deviation (MD) between -2.0 and -12.0 dB on at least one reliable test (fixation losses 33% or less, false positive rate 15% or less) * Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent) in the study eye * Confirmed glaucomatous structural damage on SD-OCT (average GCIPL and/or RNFL below age-adjusted normative mean on device-generated classification) and/or a reproducible visual field defect on Humphrey Visual Field 24-2 consistent with glaucoma, as confirmed by the enrolling glaucoma specialist at screening * Macular GCIPL and peripapillary RNFL above device-specific SD-OCT floor effect in the study eye * Currently receiving stable intraocular pressure-lowering therapy (topical medications and/or prior selective laser trabeculoplasty) for at least 4 months prior to enrollment, with no planned changes to glaucoma therapy at the time of enrollment * Intraocular pressure of 21 mmHg or less on current therapy at the screening visit in the study eye * Established patient receiving ongoing glaucoma care at University of Chicago Medicine Duchossois Center for Advanced Medicine Eye Clinic * Willing and able to provide written informed consent and comply with all study visit schedules and procedures Exclusion Criteria: * Advanced glaucoma: visual field MD worse than -12.0 dB or BCVA worse than 20/40 in the study eye * Significant retinal disease affecting macular structure or visual field, including advanced age-related macular degeneration, diabetic retinopathy greater than mild non-proliferative, clinically significant diabetic macular edema, major retinal vein occlusion, or non-glaucomatous optic neuropathy * Ocular surgery other than uncomplicated cataract extraction or selective laser trabeculoplasty within the past 6 months * Hepatic dysfunction at baseline: AST or ALT greater than 2 times the upper limit of normal, or total bilirubin greater than 1.5 times the upper limit of normal * Renal dysfunction: eGFR less than 30 mL/min/1.73 m2 * Current use of, or unwillingness to abstain from: NAD+/nicotinamide supplements, high-dose niacin or vitamin B3, Ginkgo biloba, CoQ10, isoniazid, pyrazinamide, carbamazepine, phenobarbital, primidone, or sustained-release niacin or nicotinamide formulations * Poorly controlled diabetes mellitus: HbA1c greater than 9.0% at screening * Normal tension glaucoma with documented intraocular pressure consistently 21 mmHg or less without hypotensive therapy * Participation in another investigational drug trial within 30 days of screening * Pregnancy, lactation, or intent to become pregnant during the study period * Significant cognitive impairment or inability to comply with study requirements * Clinically significant media opacity (corneal, lenticular, or vitreal) sufficient to degrade OCT signal quality below device-minimum thresholds, even if BCVA of 20/40 or better is preserved * Active or recent uveitis or intraocular inflammation in the study eye within the past 3 months * Any condition that, in the investigator's judgment, would preclude safe participation or confound result interpretation

Locations (1)

University of Chicago Medicine Duchossois Center for Advanced Medicine

Chicago, Illinois, United States